M H Raasveld, S Surachno, C E Hack, R J ten Berge. Show Affiliations »
Abstract
Entities: Disease
Mesh: See more » AdultAgedChildFemaleGraft Rejection/drug effectsHumansKidney TransplantationMiddle AgedMuromonab-CD3/adverse effectsRetrospective StudiesThromboembolism/chemically inducedThromboembolism/epidemiology
Substances: See more » Muromonab-CD3
Year: 1992 PMID: 1350035 DOI: 10.1016/0140-6736(92)92018-b
Source DB: PubMed Journal: Lancet ISSN: 0140-6736 Impact factor: 79.321